Raymond James Financial Inc Neurocrine Biosciences Inc Transaction History
Raymond James Financial Inc
- $258 Billion
- Q1 2025
A detailed history of Raymond James Financial Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Raymond James Financial Inc holds 792,482 shares of NBIX stock, worth $99.1 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
792,482
Previous 843,902
6.09%
Holding current value
$99.1 Million
Previous $115 Million
23.91%
% of portfolio
0.03%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
650Shares Held
97.2MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.77 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.24 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$692 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$608 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$334 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...